Study That Will Evaluate the Brazilian Population With COPD.
Recruiting · NCT06780046 · Observational (researchers observe without assigning treatment) · Lead sponsor: AstraZeneca
View the official record on ClinicalTrials.gov →What this trial is about
Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients of both sexes, aged 18 years or older, with confirmed COPD according to GOLD 2024: previous or current exposure and spirometry (FEV1/FVC =2 or CAT \>=10); or
- GOLD E (\>=2 moderate or 1 severe exacerbation - hospitalization); or
- GOLD 3 and 4 (FEV1 \<50%).
Exclusion criteria
- Advanced fibrosing interstitial lung disease (extent \>=50%); and/or
- High-risk pulmonary hypertension (on triple therapy); and/or
- Active cancer - on systemic therapy
Where it is running
10 locations listed.
- Research Site - Aparecida de Goiânia, Brazil
- Research Site - Bahia, Brazil
- Research Site - Belém, Brazil
- Research Site - Brasília, Brazil
- Research Site - Campo Grande, Brazil
- Research Site - Florianópolis, Brazil
- Research Site - Goiânia, Brazil
- Research Site - Santo André, Brazil
- Research Site - São Paulo, Brazil
- Research Site - Uberlândia, Brazil